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Appraisal Critically Appraised Papers
Summary of: Ferrari G, Olliveri F, De Filippi G, Milan 
A, Aprà F, Boccuzzi A, Converso M, Navalesi P (2007) 
Noninvasive positive airway pressure and risk of myocardial 
infarction in acute cardiogenic pulmonary oedema: 
Continuous positive airway pressure vs noninvasive positive 
pressure ventilation. Chest 132: 1804–1809. [Prepared by 
Mark Elkins, CAP Co-ordinator.]
Question: Acute cardiogenic pulmonary oedema (ACPO) 
can be managed with either non-invasive pressure support 
ventilation (NIPSV) or non-invasive continuous positive 
airway pressure (CPAP). Does management with NIPSV 
increase the risk of myocardial infarction compared to 
management with CPAP? Design: Randomised controlled 
trial with concealed allocation. Setting: High-dependency 
unit of a hospital emergency department in Turin, Italy. 
Patients: 52 adults with severe ACPO, defined as acute 
dyspnoea, > 30 breaths per minute, use of accessory 
respiratory muscles, oxygen saturation (SpO2) < 90% 
with FiO2 60%, and radiological signs of ACPO. Patients 
with signs of acute coronary syndrome (ACS) on hospital 
admission were excluded from the study. Interventions: 
All patients received standard medications (diuretic, 
nitroglycerin, morphine) and oxygen. NIPSV was applied 
by a Pulmonetics Systems LTV 1000 ventilator. CPAP was 
administered by means of a flow generator (Whisper-Flow) 
with an expiratory (PEEP) valve. Patients randomised to 
NIPSV (n = 25) received sufficient inspiratory pressure 
(IPAP) to generate a tidal volume of ~7 mL/kg, and oxygen 
to maintain SpO2 at ~93%, via an oronasal mask. Expiratory 
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pressure (EPAP) was gradually increased until SpO2 ≥ 96% 
(maximum of 12 cmH2O). Those randomised to CPAP (n 
= 27) commenced at 5 cmH2O via an oronasal mask with 
oxygen to maintain SpO2 at ~93%. The CPAP was gradually 
increased until SpO2 ≥ 96% (maximum of 12 cmH2O). 
Treatment failure was defined as cardiac arrest, respiratory 
distress and arterial blood gas deterioration for > 60 min, 
PaO2/FiO2 < 100 mmHg, coma or psychomotor agitation, 
haemodynamic instability, or life-threatening arrhythmias. 
Otherwise, treatment continued until the participant met 
objective criteria of recovery. Outcomes: The primary 
outcome was the rate of acute myocardial infarction 
(AMI). Secondary outcomes included rate of endotracheal 
intubation, death, duration of ventilatory assistance, and 
lengths of stay in the hospital and high-dependency unit. 
Results: In the NIPSV group, the average EPAP and IPAP 
applied were 7 ± 1 and 15 ± 3 cm H2O, respectively. In the 
CPAP group, the mean pressure applied was 9 ± 2 cm H2O. 
AMI occurred in four patients on NIPSV and eight patients 
on CPAP, which was not significantly different, absolute 
risk reduction (ARR) 0.14, 95% CI –0.10 to 0.34. Also 
not significantly different were the number of intubations 
with only one in the NIPSV group, ARR –0.04, 95% CI 
–0.20 to 0.09, and the number of deaths with three in the 
NIPSV group and two in the CPAP group, ARR –0.05, 
95% CI –0.23 to 0.13. The lengths of stay in hospital and 
in the high-dependency unit also did not significantly differ 
between the groups. Conclusion: This study demonstrated 
no significant difference in AMI among patients with ACPO 
managed with NIPSV versus CPAP.
[ARRs and CIs calculated by the CAP Co-ordinator.]
Commentary
ACPO is a vital emergency that usually occurs in the elderly 
population with a high prevalence of coronary artery 
disease. The most frequent precipitant cause has been 
reported to be ACS, especially AMI. Typically, this is a 
non-extensive non-Q wave AMI that occurs in a patient with 
previous infarction, diabetes, and hypertension. On other 
occasions, however, myocardial necrosis is due to either 
coronary flow imbalance or cardiac overload, secondary to 
the stress of ACPO. This secondary mechanism is silent, 
usually generates lower increases in cardiac biomarkers 
than primary ACS, and has been described in patients with 
normal coronary arteries.
In patients with ACPO, non-invasive ventilation has been 
shown to produce a rapid improvement in physiologic 
parameters and a reduction in the intubation rate and 
mortality (Masip 2005). Most of the series analysing this 
technique have reported the overall incidence of AMI 
considering both primary and secondary mechanisms.
The study by Ferrari et al excluded patients with ACS and 
therefore it should be inferred that all new cases of AMI were 
secondary. The trial was specifically designed to clarify 
the confusion introduced by some previous biased trials 
that described a higher AMI rate with the use of NIPSV 
compared to CPAP (Mheta 1997). Conversely, the authors 
found a nearly double AMI rate in the CPAP group, but the 
difference was not significant. The study does not provide 
extensive information about ACS exclusions or new cases 
of AMI and it is not conclusive because of the small sample 
size, but provides, like previous trials (Bellone 2004) and 
meta-analyses, greater evidence about the neutral effect of 
NIPSV on the incidence of AMI.
Josep Masip
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